Exportar registro bibliográfico


Metrics:

A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas (2020)

  • Authors:
  • Autor USP: FRANCISCO, ROSSANA PULCINELI VIEIRA - HU
  • Unidade: HU
  • DOI: 10.1007/s11102-019-01008-z
  • Subjects: ABORTO; AGENTES DOPAMINÉRGICOS; COMPLICAÇÕES DO TRABALHO DE PARTO; ESTUDOS RETROSPECTIVOS
  • Language: Inglês
  • Imprenta:
  • Source:
    • Título do periódico: Pituitary
    • ISSN: 1386-341X
    • Volume/Número/Paginação/Ano: v. 23, n. 2, p. 120-128, 2020
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1007/s11102-019-01008-z (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ANNA, B. G. Sant; LYRA, R; MARTINS, M. R. A; et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary, New York, v. 23, n. 2, p. 120-128, 2020. Disponível em: < https://observatorio.fm.usp.br/handle/OPI/36018 > DOI: 10.1007/s11102-019-01008-z.
    • APA

      Anna, B. G. S., Lyra, R., Martins, M. R. A., Francisco, R. P. V., Musolino, N. R. C., Gadelha, M. R., et al. (2020). A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary, 23( 2), 120-128. doi:10.1007/s11102-019-01008-z
    • NLM

      Anna BGS, Lyra R, Martins MRA, Francisco RPV, Musolino NRC, Gadelha MR, Marques C, Castro M, Elias PCL, Vilar L. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas [Internet]. Pituitary. 2020 ; 23( 2): 120-128.Available from: https://observatorio.fm.usp.br/handle/OPI/36018
    • Vancouver

      Anna BGS, Lyra R, Martins MRA, Francisco RPV, Musolino NRC, Gadelha MR, Marques C, Castro M, Elias PCL, Vilar L. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas [Internet]. Pituitary. 2020 ; 23( 2): 120-128.Available from: https://observatorio.fm.usp.br/handle/OPI/36018

    Referências citadas na obra
    Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol 25(5):549–554
    Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 16:185–217
    Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331
    Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10(4):333–337
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904–909
    Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A et al (1986) Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63(4):941–945
    Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5(2):55–65
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288
    Mehta AE, Tolis G (1979) Pharmacology of bromocriptine in health and disease. Drugs 17(5):313–325
    Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823–827
    Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 172(5):R205–R213
    Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85(2):217–220
    Hu Y, Ding Y, Yang M, Xiang Z (2018) Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab Med 56(5):803–807
    Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65(4):461–474
    Persiani S, Sassolas G, Piscitelli G, Bizollon CA, Poggesi I, Pianezzola E et al (1994) Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 83(10):1421–1424
    Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P et al (1979) A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48(1):9–12
    Beltrame D, Longo M, Mazué G (1996) Reproductive toxicity of cabergoline in mice, rats, and rabbits. Reprod Toxicol 10(6):471–483
    Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121–1126
    Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73(2):236–242
    Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350
    Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8(1):31–38
    Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95(6):2672–2679
    Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22(3):239–246
    Bronstein MD, Salgado LR, de Castro Musolino NR (2002) Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 5(2):99–107
    Karaca Z, Yarman S, Ozbas I, Kadioglu P, Akturk M, Kilicli F et al (2018) How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey. J Endocrinol Investig 41(1):129–141
    Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270–273
    Galvão A, Gonçalves D, Moreira M, Inocêncio G, Silva C, Braga J (2017) Prolactinoma and pregnancy—a series of cases including pituitary apoplexy. J Obstet Gynaecol 37(3):284–287
    Araujo B, Belo S, Carvalho D (2017) Pregnancy and Tumor Outcomes in Women with Prolactinoma. Exp Clin Endocrinol Diabetes 125(10):642–648
    Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR et al (2017) Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes. Obstet Gynecol 129(1):185–194
    Glezer A, Bronstein MD (2017) Prolactinomas: how to handle prior to and during pregnancy? Minerva Endocrinol 43(4):423–429
    Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312(21):1364–1370
    Gemzell C, Wang CF (1979) Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 31(4):363–372
    Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with prolactinoma–effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol 111(4):452–459
    Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE et al (1988) Incidence of early loss of pregnancy. N Engl J Med 319(4):189–194
    Hemminki E, Forssas E (1999) Epidemiology of miscarriage and its relation to other reproductive events in Finland. Am J Obstet Gynecol 181(2):396–401
    Cecatti JG, Guerra GV, Sousa MH, Menezes GM (2010) Abortion in Brazil: a demographic approach. Rev Bras Ginecol Obstet 32(3):105–111
    Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B et al (2016) Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet 388(10041):258–267
    Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C (2014) Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 290(2):263–270
    Bachelot A, Binart N (2007) Reproductive role of prolactin. Reproduction 133(2):361–369
    Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P (2013) Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab 98(10):3920–3925
    Vila G, Akerblad AC, Mattsson AF, Riedl M, Webb SM, Hána V et al (2015) Pregnancy outcomes in women with growth hormone deficiency. Fertil Steril 104(5):1210–7.e1
    Betrán AP, Ye J, Moller AB, Zhang J, Gülmezoglu AM, Torloni MR (2016) The increasing trend in caesarean section rates: global, regional and national estimates: 1990–2014. PLoS ONE 11(2):e0148343
    Ferreira EC, Pacagnella RC, Costa ML, Cecatti JG (2015) The Robson ten-group classification system for appraising deliveries at a tertiary referral hospital in Brazil. Int J Gynaecol Obstet 129(3):236–239
    Bolognani CV, Reis LBSM, Dias A, Calderon IMP (2018) Robson 10-groups classification system to access C-section in two public hospitals of the Federal District/Brazil. PLoS ONE 13(2):e0192997
    Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791–793
    Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 68(1):66–71
    Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol 80(5):642–648
    Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R et al (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162–2172
    Blanc AK, Wardlaw T (2005) Monitoring low birth weight: an evaluation of international estimates and an updated estimation procedure. Bull World Health Organ 83(3):178–185
    Kalter H, Warkany J (1983) Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med 308(8):424–431
    Glezer A, Bronstein MD (2014) Prolactinomas, cabergoline, and pregnancy. Endocrine 47(1):64–69
    Mitsiakos G (2019) A possible role of GDNF expression by which cabergoline use affects corpus callosum. J Pediatr Neonatal Individ Med 8:e080112
    van Gool JD, Hirche H, Lax H, De Schaepdrijver L (2018) Folic acid and primary prevention of neural tube defects: a review. Reprod Toxicol 80:73–84
    Zárate A, Canales ES, Alger M, Forsbach G (1979) The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol 92(3):407–412
    Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379
    Rjosk HK, Fahlbusch R, von Werder K (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol 100(3):337–346
    Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) Is pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4(8):910–912
    Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 44(3):175–180
    Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol 72(4):507–511

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2021